Low doses of Aprotinin aortocoronary bypass surgery - Advantages and disadvantages

Medical Science Monitor

Volumn 6, Issue 4, 2000, Pages 722-728

  Golanski, R ^a   Golanski, J ^a   Chizynski, K ^a   Iwaszkiewicz, A ^a   Zaslonka, J ^a   Pietrucha, T ^a   Chrul, S ^a   Watala, C ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Aortocoronary bypass surgery; Aprotinin; Hemostatic disorders; Platelet activation

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN III; APROTININ; CREATINE KINASE MB; D DIMER; FIBRINOGEN; GLYCOPROTEIN IB; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN I;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DRUG SAFETY; FEMALE; FIBRINOLYSIS; FLOW CYTOMETRY; HEART INFARCTION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOEMBOLISM;

AGED; APROTININ; BLOOD COAGULATION; CORONARY ARTERY BYPASS; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; POSTOPERATIVE HEMORRHAGE; SERINE PROTEINASE INHIBITORS; THROMBOEMBOLISM;

EID: 0033851107     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. The platelet function defect of cardiopulmonary bypass
2. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss
3. Activation of coagulation and fibrinolysis during cardiothoracic operations
4. The platelet in cardiopulmonary bypass
5. Zmiany w ukladzie fibrynolizy u pacjentow poddawanych operacjom w krazeniu pozaustrojowym - Doniesienie wstepne
6. Intra and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery
7. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass
8. Characterization of Prothrombin Activation during Cardiac Surgery by Molecular Markers
9. Endothelial cell injury in cardiovascular surgery: The procoagulant response
10. Early activation of hemostasis during cardiopulmonary bypass: Evidence for thrombin mediated hyperfibrinolysis
11. Modulation of Platelet Surface Adhesion Receptors During Cardiopulmonary Bypass
12. Modulation of surface platelet membrane receptors in patients with coronary artery disease during cardiopulmonary bypass - A preliminary report
13. Bleeding complications associated with cardiopulmonary bypass
14. Treatment of excessive mediastinal bleeding after cardiopulmonary bypass
15. Inflamatory Response to Cardiopulmonary Bypass
16. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass
17. Preoperative platelet dysfunction increases the benefit of aprotinin in cardiopulmonary bypass
18. Aprotinin inhibits the contact, neutrophil, and platelet activation systems durning simulated extracorporeal perfusion
19. The efficacy and safety of aprotinin use in cardiac surgery
20. Nafamostat mesilate, a broad spectrum protease inhibitor, modulates platelets, neutrophil, and contact activation in simulated extracorporeal circulation
21. Thrombin and human plasma kallikrein inhibition during simulated extracorporeal circulation block platelet and neutrophil activation
22. Differentiation between transmural perioperative myocardial infarction and subendocardial injury after coronary artery bypass grafting using biochemical tests, elaborated by cluster and discriminant analysis
23. Cardiac troponin I plasma levels for diagnosis and quantitation of perioperative myocardial damage in patients undergoing coronary artery bypass surgery
24. Are electrocardiographic Q-wave criteria reliabte for diagnosis of perioperative myocardial infarction after coronary surgery?
25. Use of flow cytometry to differentiate between activation and reactivity of blood platelets
26. Low-dose and high-dose aprotinin improve hemostasis in coronary operations
27. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery
28. Intraoperative local fibinolysis as emergency therapy aider early coronary artery thrombosis
29. Aortocoronary Saphenous Vein Graft Disease
30. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations
31. Aprotinin Modulation of Platelet Action in Patients Undergoing Cardiopulmonary Bypass Operations
32. Aprotin Has no Effect on Platelet Activation and Adhesion during Cardiopulmonary Bypass
33. Aprotinin in Aortocoronary Bypass Surgery: Increased Risk of Vein-Graft Occlusion and Myocardial Infarction? Supportive Evidence from a Retrospeetive Study
34. Aprotinin and Dipyridamole for the Safe Redustion of Postoperative Blood Loss
35. Randomized Study of Aprotinin and DDAVP to Reduce Postoperative Bleeding After Cardiopulmonary Bypass Surgery
36. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis
37. Analyses of Coronary Graft Patency After Aprotinin Use: Results from the International Multicenter Aprotinin Graft Potency Experience (IMAGE) Trial
38. Aprotinin and vein graft occlusion - The controversy continues